Belite Bio, Inc. Sponsored ADR

BLTE Healthcare Biotechnology

EPS
−40.0%
Free cash flow
+64.7%

Quarter to June 2026, against a year earlier

154.46 11.27 +7.87%
Market cap
$5.8B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Belite Bio, Inc. Sponsored ADR (BLTE) Free cash flow

Alert me on Free cash flow

Belite Bio, Inc. Sponsored ADR's free cash flow for fiscal 2025 was −$37.2M, compared with −$29.4M in fiscal 2024. Over the past ten years it has ranged from −$37.2M (fiscal 2025) to −$4.5M (fiscal 2020) — the current reading is the lowest in ten years. Belite Bio, Inc. Sponsored ADR ranks 384th of 603 Biotechnology companies by free cash flow.

Free cash flow, annual

Embed this chart

Annual newest first

Period Free cash flow Change
FY2025 −$37.2M —
FY2024 −$29.4M —
FY2023 −$29.9M —
FY2022 −$11.9M —
FY2021 −$7.5M —
FY2020 −$4.5M —

Quarterly newest first

Period Free cash flow Change
Dec 2025 −$10.6M —
Sep 2025 −$26.6M —
Dec 2024 −$4.6M —
Sep 2024 −$24.8M —
6 more quarters

Against its own ten years

Low −$37.2M High −$4.5M
Ten-year median −$20.6M
Current reading's percentile 17

Free cash flow against peers

What Free cash flow is

Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.

Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)

The full definition of Free cash flow →

More on BLTE